Literature DB >> 26235683

Recurrence in patients with stage I colorectal cancer.

Patrick Ely Teloken1, David Ransom2, Ian Faragher3, Ian Jones4, Peter Gibbs5, Cameron Platell6,7.   

Abstract

BACKGROUND: Outcomes of patients with stage I colorectal cancer submitted to surgery with curative intent have not been thoroughly explored in contemporary series.
METHODS: All patients with colon or rectal adenocarcinoma who underwent resection from the St John of God Hospital (1996-2013) and BioGrid (1991-2013) databases were identified. Patients submitted to local excision, polypectomies or neoadjuvant treatment were excluded. Outcomes included recurrence (combined local and systemic), recurrence-free and overall survival, and survival after recurrence.
RESULTS: A total of 1193 patients with stage I disease were included. Median age was 67 (interquartile range 59-75) and median follow-up was 3.2 years (interquartile range 1.4-5.8). Five-year recurrence rate was 7.1% (95% confidence interval (CI) 5.4-9.4%; 5.0% for colon and 11.1% for rectal cancer). Rectal location was an independent predictor of recurrence (hazard ratio (HR) 1.97, 95% CI 1.09-3.55; P = 0.024). Lymphovascular invasion was an independent predictor of recurrence only in patients with rectal cancer (HR 3.0, 95% CI 1.2-7.6; P = 0.018). Five-year recurrence-free survival was 83.2% (95% CI 80.3-85.4%). Age (HR 1.05, 95% CI 1.03-1.07; P < 0.001), elective surgery (HR 0.41, 95% CI 0.21-0.80; P = 0.011) and the American Society of Anesthesiologists (ASA) score (HR 3.08, 95% CI 1.51-6.31; P < 0.001) were independently associated with recurrence-free survival. Median survival after recurrence was 41 months. Resection of recurrence was attempted in 39% of patients.
CONCLUSION: Patients with stage I colorectal cancers still have a clinically significant risk of recurrence. Rectal location is independently associated with higher recurrence. Age, elective surgery and ASA are independently associated with recurrence-free survival. A significant proportion of patients with recurrence underwent further resection.
© 2015 Royal Australasian College of Surgeons.

Entities:  

Keywords:  colon cancer; rectal cancer; recurrence; surveillance

Mesh:

Year:  2015        PMID: 26235683     DOI: 10.1111/ans.13254

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  6 in total

1.  Identification of Recurrence-Predictive Indicators in Stage I Colorectal Cancer.

Authors:  Jun Ho Lee; Jong Lyul Lee; In Ja Park; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

2.  Identification of high-risk stage I colon and rectal cancer patients: a retrospective analysis of a large Japanese cohort.

Authors:  Yudai Fukui; Koya Hida; Nobuaki Hoshino; Daisuke Nishizaki; Ryosuke Okamura; Shinichi Yamauchi; Kenichi Sugihara; Yoshiharu Sakai
Journal:  Int J Colorectal Dis       Date:  2022-05-19       Impact factor: 2.796

3.  Identification of a Subset of Stage I Colorectal Cancer Patients With High Recurrence Risk.

Authors:  Lik Hang Lee; Lindy Davis; Lourdes Ylagan; Angela R Omilian; Kristopher Attwood; Canan Firat; Jinru Shia; Philip B Paty; William G Cance
Journal:  J Natl Cancer Inst       Date:  2022-05-09       Impact factor: 11.816

4.  Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer.

Authors:  Jonah Popp; David S Weinberg; Eva Enns; John A Nyman; J Robert Beck; Karen M Kuntz
Journal:  Value Health       Date:  2021-10-13       Impact factor: 5.101

5.  The outcome of intravenous and inhalation anesthesia after pancreatic cancer resection: a retrospective study.

Authors:  Yu Wang; Liping Wang; Jie Ren; Junli Wang; Jingwen Chen; Yue Ma; Yutong Yang; Ming Wei
Journal:  BMC Anesthesiol       Date:  2022-05-30       Impact factor: 2.376

6.  Cost-effectiveness of adding Endocuff® to standard colonoscopies for interval colorectal cancer screening.

Authors:  Tiffany M Yu; Alison Tradonsky; Jun Tang; Renée Jg Arnold
Journal:  Clinicoecon Outcomes Res       Date:  2019-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.